News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Phase II clinical trial starts evaluating new drug for glioblastoma

Al's Comment:

GDC-0084 (RG7666) which is a novel BBB-penetrating PI3K/mTOR inhibitor displaying a high brain-to-plasma ratio (1.9–3.3). It remarkably impedes the proliferation of five GBM cell lines and suppresses the growth of U-87 MG GBM xenografts through decreasing Akt phosphorylation 


Posted on: 04/06/2018

Phase II clinical trial starts evaluating new drug for glioblastoma

https://www.epmmagazine.com/news/clinical-trial-starts-evaluating-new-drug-for-glioblastoma/

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740